$MRZM Signs LOI With Chromocell to Acquire or License

New Post Public Reply Private Reply Replies (0) Message Board
SpotlightGrowth1
219
$MRZM Signs LOI With Chromocell to Acquire or License Assets

*PR was released after hours around 5pm EST 3/18/19

FORT COLLINS, Colo., March 18, 2019 (Newswire.com) – Marizyme, Inc. (“Marizyme” or the “Company”), a publicly traded (OTC: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space and related areas, announced today that they signed a Letter of Intent to evaluate the licensing or acquisition of certain non-opiate pain relief and rare disease assets from Chromocell Corporation (“Chromocell”), pending further due diligence from both companies.

Mr. James Sapirstein, Executive Chairman of Marizyme, Inc., commented: “This opportunity is a perfect fit with Marizyme’s strategic direction. We are very pleased to work with Chromocell and proceed with the due diligence process.”

The treatment of acute and chronic pain remains a significant challenge, due to insufficient efficacy, negative side effects and abuse potential of currently available therapeutics. Chromocell’s discovery and development programs are focused on the development of breakthrough therapeutics for neuropathic and nociceptive pain. Chromocell’s lead candidate CC8464 has completed Phase 1 clinical trials in the United States.

Mr. Christian Kopfli, Chief Executive Officer of Chromocell, Inc. said: “Evaluating a partnership with Marizyme to bring our products to market is an exciting development for our company. Non-opiate analgesics are critical for treating patients with acute and chronic pain.”

About Marizyme, Inc.

Marizyme, Inc. is a development-stage company dedicated to the commercialization of therapies that address the urgent need of higher mortality and costs in the acute care space. Specifically, Marizyme will focus its efforts on developing treatments for disease caused by thrombus (stroke, acute myocardial infarctions or AMIs and deep vein thrombosis or DVTs), and chronic wound care conditions. These conditions combine for over $26 billion dollars in potential market opportunity and are responsible for sending over millions of patients to the hospital every year in the U.S. alone.

The Company’s first product candidates are derived from Krillase™ Technology, a broad intellectual property portfolio around a novel system of proteolytic enzymes. Marizyme completed the acquisition of these assets and intends to develop several product candidates that will address unmet medical needs in the acute care setting. For more information about the Company, visit www.marizyme.com.

About Chromocell

Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromocell’s therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert® technology has proven highly effective in the rapid identification of potential new drug candidates.

Forward-Looking Statements

This press release contains certain forward-looking statements, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable and complete. However, a variety of factors, many of which are beyond the Company’s control, affect the Company’s operations, performance, business strategy and results and there can be no assurances that the Company’s actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Disclaimer:

Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.

All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash by a third party for the creation and dissemination of this content.

This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.

The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.

Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: http://spotlightgrowth.com/index.php/disclosures/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Five SEAL Medal of Honor Signatures, One Charity Lot

Updated Category News Views 74

A single rifle can carry a staggering amount of meaning when the names on it belong to all five living U.S. Navy SEAL Medal of Honor recipients. Rock Island Auction Company plans to offer that one-of-a-kind custom precision rifle during its December 4–6, 2026 Premier Firearms Auction, and the financial arrangement is unusually clean: 100% of proceeds are slated for the...

Continue Reading
Trip.Best Expands Global Travel Discovery Footprint

Updated Category News Views 64

Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...

Continue Reading
Point72 Breach Puts Cyber Controls Under the Microscope

Updated Category News Views 76

Two compromised user accounts can turn a supposedly contained cyber problem into a boardroom headache in a hurry. Point72 Asset Management, the global alternative-investment firm founded by Steven A. Cohen in 2014, has reported a social-engineering incident involving accounts that were used to copy files from limited portions of its IT systems. This is not a trading-loss...

Continue Reading
Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 79

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 150

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading
SQM Investigation Puts Chile Approval Claims on Trial

Updated Category News Views 42

A Regulatory Promise Meets a Rough Earnings Reaction A 5.52% haircut after disappointing quarterly numbers is the sort of thing that makes shareholders stop pretending every loose management comment is harmless. Sociedad Química y Minera de Chile, NYSE:SQM, is facing an investigation by Levi & Korsinsky into public statements concerning regulatory matters, particularly...

Continue Reading
Würk's Bryte AI Targets Payroll's Costly Friction Points

Updated Category News Views 104

Payroll mistakes are the sort of paper cuts that suddenly turn into a hospital bill for an employer. Würk’s Nov. 19 launch of Bryte AI goes straight at that ugly reality in cannabis, beverage alcohol, and other heavily regulated workplaces, where a bad time entry, missed document, or misunderstood policy can create a far more expensive mess than ordinary office...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 135

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 72

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading

Top 5 Most Recently Viewed Articles

Priority Plumbing & Heating Expands with New Boiler Services

Updated Category News Views 215

Priority Plumbing & Heating Expands to Meet Growing Demand Priority Plumbing & Heating, a notable provider of home services, is delighted to announce the expansion of its offerings to include specialized boiler repair and installation services. This strategic move aims to meet the increasing demand for advanced heating systems among homeowners and businesses situated...

Continue Reading
TGS Secures Major 4D Streamer Contracts in Norway

Updated Category News Views 314

Major Contracts Awarded to TGS for 4D Streamer Campaign TGS, a leading provider of energy data and intelligence, has exciting news to share regarding its latest venture in offshore operations. The company has successfully secured contracts for four 4D streamer acquisition projects, marking a significant step forward in their commitment to provide high-quality energy data....

Continue Reading
Stanley Black & Decker: Solid Growth Amidst Challenges

Updated Category News Views 102

Stanley Black & Decker's Growth Initiatives Stanley Black & Decker, Inc. (NYSE: SWK) is currently executing an aggressive cost-reduction program aimed at enhancing its financial performance. This plan involves resizing the organization, streamlining inventory, and optimizing the supply chain. The overarching goal is to reshape the company for sustainable growth in the...

Continue Reading
Armada Partners with US Department of Energy on Genesis Mission

Updated Category News Views 185

Armada's Collaboration with the US Department of Energy Armada has announced a significant collaboration with the U.S. Department of Energy (DOE) related to the Genesis Mission. This ambitious initiative aims to modernize the approach to scientific research across the country. The Genesis Mission seeks to integrate various technological resources and national laboratories...

Continue Reading
Exploring MercadoLibre's Recent Options Activity Trends

Updated Category News Views 200

Understanding Recent Options Trends for MercadoLibre In the intriguing world of options trading, a substantial number of investors are signaling optimism about MercadoLibre (MELI). Recent activities indicate a notable bullish sentiment that retail traders should definitely pay attention to. Today's market data reveals an extraordinary series of trades, sparking curiosity...

Continue Reading